Crucell Announces STAR Technology Research License Agreement

18-Sep-2006

Crucell N.V. announced that it has started an evaluation program with Novartis AG. The program will apply Crucell's STAR(TM) technology for the selection of biopharmaceuticals production cell lines and to adapt such procedures to specific parental cell lines. The program will be performed with different monoclonal antibodies. Further details were not disclosed.

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous